Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy

Table 3

Results of serum-antibody measurements.

	N-irAEs group	DD group
ANA	3/20 (15%)	0/11 (0%)
Antineuronal antibodies	1/13 (8%)	0/4 (0%)
Myositis antibodies	0/8 (0%)	0/2 (0%)
Myasthenic antibodies	4/10 (40%)	0/1 (0%)
Autoimmune encephalitis antibodies	1/11 (9%)	0/4 (0%)
Others	3/20 (15%)	1/11 (9%)

Numbers indicate positive patients/all patients tested. Ab: antibodies; ANA: antineuronal antibodies; DD: differential diagnosis; N-irAEs: neurological adverse events. Others: GM-1-antibody (n = 1), Jo-1-antibody (n = 1), Ro-antibody (n = 2).